Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NephrosNEPH +0.23%67 EBITDA Margin % is 20.61% as of Jun. 2026. GuruFocus rates NEPH with a GF Score™ of 67/100 and a GF Value™ of $2.97 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Nephros ranks better than 52.7% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Nephros's EBITDA for the
three
months ended in Jun. 2026 was $1.24 Mil. Nephros's Revenue for the
three
months ended in Jun. 2026 was $6.02 Mil. Therefore, Nephros's EBITDA margin for the quarter that ended in Jun. 2026 was 20.61%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Nephros EBITDA Margin % Related Terms
Nephros EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Nephros's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NEPH vs MLSS, POCI, HBIO: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, Nephros's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nephros EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nephros's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Nephros's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nephros (NEPH) has a EBITDA Margin % of 20.61% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Nephros and its competitors. According to the industry distribution chart, Nephros ranks #386 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 47.3%.
Is Nephros' EBITDA Margin % too high?
Nephros' current EBITDA Margin % is 20.61%. The Medical Devices & Instruments industry median EBITDA Margin % is 7.59. Nephros' value of 20.61% is 171.5% above this industry median. Based on the distribution chart, Nephros ranks #386 out of 816 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Nephros has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nephros' EBITDA Margin % compare to MLSS and POCI?
According to the Medical Devices & Instruments industry distribution chart, Nephros ranks #386 out of 816 companies for EBITDA Margin %. This puts Nephros in the upper half of its industry. The industry median EBITDA Margin % is 7.59. Nephros' value of 20.61% is 171.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.59, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nephros's current EBITDA Margin % of 20.61% is 171.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Nephros and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nephros's current EBITDA Margin % is 20.61%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nephros stock overvalued right now?
Based on GuruFocus' analysis, Nephros (NEPH) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.97, compared to a current price of $4.42 — trading 48.8% above its estimated fair value. The current EBITDA Margin % is 20.61% and 171.5% above the Medical Devices & Instruments industry median of 7.59. Nephros' overall GF Score™ is 67/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Nephros (NEPH), the current EBITDA Margin % is 20.61% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nephros (NEPH) Overvalued in 2026?
Based on GuruFocus' analysis, Nephros stock appears to be overvalued.
The current stock price of $4.42 is trading 48.8% above its estimated GF Value™ of $2.97.
GuruFocus considers Nephros to be Significantly Overvalued.
Key valuation signals for NEPH:
EBITDA Margin %: 20.61%
GF Value™: $2.97 vs. price of $4.42 (48.8% above fair value)
Industry Position: 171.5% above the Medical Devices & Instruments median (#386 of 816)
No single metric tells the full story. See the NEPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of revenue from product sales and a small amount from royalty revenue and other revenues.
67GF Score
Get the complete analysis for NEPH
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NEPH has been successfully added to your 
